Bempegaldesleukin
Also known as: BEMPEG, bempegaldesleukin, CD122-biased IL-2, NKTR-214, NKTR‑214, PEG‑IL‑2
Source Bempegaldesleukin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bempegaldesleukin (NKTR‑214) is a PEG‑modified IL‑2 prodrug under clinical investigation as an immuno‑oncology agent, typically administered subcutaneously in combination with checkpoint inhibitors.
Mechanism of Action
Biases activation toward the IL‑2Rβγ (CD122/CD132) complex, preferentially expanding CD8⁺ T cells and NK cells while limiting Treg stimulation, thereby enhancing antitumor immunity.
Routes of Administration
Goals & Uses
- MelanomaOncologyModerate
- Metastatic melanoma treatmentOncologyModerate
- Regulatory T cell suppression reductionImmunologyModerate
- Renal cell carcinoma treatmentOncologyLow
- Anti-tumor immunity enhancementOncologyModerate
- Urothelial carcinoma treatmentOncologyModerate
- Non‑small cell lung cancerOncologyLow
- anti‑tumor immune activationOncologyModerate
- Renal cell carcinomaOncologyModerate
Contraindications
- Organ transplantationTransplantHigh
- Poor performance status (ECOG ≥2)Clinical StatusModerate
- Severe autoimmune diseaseImmunologicalHigh
- Known hypersensitivity to bempegaldesleukin or its excipientsAllergyHigh
- hypersensitivity to bempegaldesleukin or excipientsAllergyHigh
- Prior severe IL-2 toxicityPrior Adverse ReactionHigh
- Active severe infectionInfectiousHigh
- Active, uncontrolled autoimmune diseaseImmuneModerate
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Cytokine release syndromeImmunologicUncommonSystemic inflammatory response from immune activation
- Edema/fluid retentionFluid BalanceUncommon
- Flu-like symptoms (fever, chills, fatigue)ConstitutionalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Fever/chillsConstitutionalCommon
- Rash/skin toxicityDermatologicalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- FatigueGeneralCommonLow energy or tiredness
- Immune-mediated adverse eventsImmunologicalUncommon
- Rash/pruritusDermatologicCommon
- Infusion-related reactionsHypersensitivityCommon
Drug Interactions
- High‑dose corticosteroidsModerate
- Nivolumab (anti-PD-1)Moderate
- Cytochrome P450 inhibitorsLow
- Ipilimumab (anti-CTLA-4)Moderate
- Pembrolizumab (anti-PD-1)Moderate
- other cytokine therapiesHigh
- CorticosteroidsModerate
- Other cytokine therapies (e.g., IL‑2, IL‑15)High
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Pregnant womenReproductiveRelative
- Patients with hepatic or renal impairmentOrgan ImpairmentRelative
- Patients with organ transplantsImmunologicalRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing; not authorized.
- United StatesInvestigationalUnder IND; Phase 2/3 trials.
- United KingdomInvestigationalBeing evaluated in NHS-sponsored studies.
In Phase 2/3 trials for several solid tumours; not approved in any jurisdiction as of 2024.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Bempegaldesleukin?
Bempegaldesleukin (NKTR‑214) is a PEG‑modified IL‑2 prodrug under clinical investigation as an immuno‑oncology agent, typically administered subcutaneously in combination with checkpoint inhibitors.
What is Bempegaldesleukin used for?
Bempegaldesleukin is educationally associated with: Melanoma, Metastatic melanoma treatment, Regulatory T cell suppression reduction, Renal cell carcinoma treatment, Anti-tumor immunity enhancement, Urothelial carcinoma treatment, Non‑small cell lung cancer, anti‑tumor immune activation, Renal cell carcinoma. Educational only — not medical advice.
How is Bempegaldesleukin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Bempegaldesleukin?
Reported adverse effects include: Cytokine release syndrome, Edema/fluid retention, Flu-like symptoms (fever, chills, fatigue), Hypotension, Fever/chills, Rash/skin toxicity, Nausea, Fatigue, Immune-mediated adverse events, Rash/pruritus, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Bempegaldesleukin?
Recorded contraindications: Organ transplantation, Poor performance status (ECOG ≥2), Severe autoimmune disease, Known hypersensitivity to bempegaldesleukin or its excipients, hypersensitivity to bempegaldesleukin or excipients, Prior severe IL-2 toxicity, Active severe infection, Active, uncontrolled autoimmune disease, Active autoimmune disease. Consult a qualified clinician before use.